February 11, 2020 6:25 AM EST
Bionic Bliss CBD Agriculture and Consumer Services also spoke at the FDA meeting and said, “Without the FDA’s guidance and leadership, individual states may carve out their own regulatory exceptions for CBD. We urge the FDA to resolve the statutory issues and properly establish a legal pathway for CBD products to enter the market place.” FDA principal deputy commissioner Dr. Amy Abernethy summarized the key points from Friday’s public meeting, including a need to “further clarify the regulatory framework to reduce confusion in the market,” to conduct and gather additional scientific research and data on CBD usage on humans and animals, to create labeling standards, safety thresholds for dosing, and quality standards that include lab testing and data analyses. The FDA regulators have opened a public docket in conjunction with last week’s public meeting. Until July 2, any member of the general public can
https://pillsenergy.com/bionic-bliss-cbd/